

OCT 02 2008

3/12


U.S.S.N. 10/561,571  
CASE NO. 21406YP  
PAGE NO. 2**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listing of claims in the application.

Cancel claims 1, 3-9 and 12-15 and replace them with new claims 16-24 as follows:

16(New).


A compound of the structural formula I:



Formula I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof:  
wherein,

M, M1, and M2, independently are CH;



R represents hydrogen, or C<sub>1-6</sub> alkyl;

X represents -(CHR<sub>7</sub>)<sub>p</sub>-;

Y represents -(CH<sub>2</sub>)<sub>r</sub>-, -CO(CH<sub>2</sub>)<sub>n</sub>-, -SO<sub>2</sub>-, -O-, -S-, -CH(OR')-, or CONR';

R' represents hydrogen, C<sub>1-10</sub> alkyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>1-6</sub> alkoxy, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3-8</sub> cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3-10</sub> heterocyclyl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from Ra;

or, R' and R<sub>6</sub> taken together with the intervening N atom of CONR' of Y to form a 4-10 membered carbocyclic or heterocyclic ring optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from Ra;

U.S.S.N. 10/561,571  
CASE NO. 21406YP  
PAGE NO. 3

Q represents N, CRY, or O, wherein R<sub>2</sub> is absent when Q is O;

R<sub>Y</sub> represents H, C<sub>1-10</sub> alkyl, C<sub>1-6</sub> alkylSR, -(CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>m</sub>OR,  
-(CH<sub>2</sub>)<sub>n</sub>C<sub>1-6</sub> alkoxy, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3-8</sub> cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3-10</sub> heterocyclyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>5-10</sub> heteroaryl, -N(R)<sub>2</sub>, -COOR, or -(CH<sub>2</sub>)<sub>n</sub>C<sub>6-10</sub> aryl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-5 groups selected from Ra;

or, R<sub>2</sub>-Q-R<sub>3</sub> form a 3-15 membered carbocyclic or heterocyclic ring or fused ring, optionally interrupted by 1-3 atoms of O, S, C(O) or NR, and optionally having 1-5 double bonds, and optionally substituted by 1-3 groups selected from Ra;

R<sub>w</sub> represents H, C<sub>1-6</sub> alkyl, -C(O)C<sub>1-6</sub> alkyl, -C(O)OC<sub>1-6</sub> alkyl, -SO<sub>2</sub>N(R)<sub>2</sub>, -SO<sub>2</sub>C<sub>1-6</sub> alkyl, -SO<sub>2</sub>C<sub>6-10</sub> aryl, NO<sub>2</sub>, CN or -C(O)N(R)<sub>2</sub>;

R<sub>2</sub> represents hydrogen, C<sub>1-10</sub> alkyl, C<sub>1-6</sub> alkylSR, -(CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>m</sub>OR,  
-(CH<sub>2</sub>)<sub>n</sub>C<sub>1-6</sub> alkoxy, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3-8</sub> cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3-10</sub> heterocyclyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>5-10</sub> heteroaryl, -N(R)<sub>2</sub>, -COOR, or -(CH<sub>2</sub>)<sub>n</sub>C<sub>6-10</sub> aryl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from Ra;

R<sub>3</sub> represents hydrogen, C<sub>1-10</sub> alkyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3-8</sub> cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3-10</sub> heterocyclyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>5-10</sub> heteroaryl, -(CH<sub>2</sub>)<sub>n</sub>COOR, -(CH<sub>2</sub>)<sub>n</sub>C<sub>6-10</sub> aryl, -(CH<sub>2</sub>)<sub>n</sub>NHR<sub>8</sub>, -(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>, -(CH<sub>2</sub>)<sub>n</sub>NHCOOR, -(CH<sub>2</sub>)<sub>n</sub>N(R<sub>8</sub>)CO<sub>2</sub>R, -(CH<sub>2</sub>)<sub>n</sub>N(R<sub>8</sub>)COR, -(CH<sub>2</sub>)<sub>n</sub>NHCOR, -(CH<sub>2</sub>)<sub>n</sub>CONH(R<sub>8</sub>), aryl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>1-6</sub> alkoxy, CF<sub>3</sub>, -(CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>R, -(CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>N(R)<sub>2</sub>, -(CH<sub>2</sub>)<sub>n</sub>CON(R)<sub>2</sub>, -(CH<sub>2</sub>)<sub>n</sub>CONHC(R)<sub>3</sub>, -(CH<sub>2</sub>)<sub>n</sub>COR<sub>8</sub>, nitro, cyano or halogen, said alkyl, alkoxy, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups of Ra;

R<sub>4</sub> and R<sub>5</sub> independently represent hydrogen, C<sub>1-6</sub> alkoxy, OH, C<sub>1-6</sub> alkyl, SO<sub>3</sub>H, (CH<sub>2</sub>)<sub>n</sub>OPO(OH)<sub>2</sub>, O(CH<sub>2</sub>)<sub>n</sub>OPO(OH)<sub>2</sub>, CF<sub>3</sub>, nitro, or halogen where said alkyl, and alkoxy, are optionally substituted with 1-7 groups of Ra;

R<sub>6</sub> represents hydrogen, C<sub>1-10</sub> alkyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>6-10</sub> aryl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>5-10</sub> heteroaryl, (C<sub>6-10</sub> aryl)O-, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3-10</sub> heterocyclyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3-8</sub> cycloalkyl, -COOR, -C(O)CO<sub>2</sub>R, said aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from Ra;

U.S.S.N. 10/561,571  
CASE NO. 21406YP  
PAGE NO. 4

R<sub>7</sub> represents hydrogen, C<sub>1</sub>-6 alkyl, -(CH<sub>2</sub>)<sub>n</sub>COOR or -(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>,

R<sub>8</sub> represents -(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-8 cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub> 3-10 heterocyclyl, C<sub>1</sub>-6 alkoxy or -(CH<sub>2</sub>)<sub>n</sub>C<sub>5</sub>-10 heteroaryl, said heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from R<sup>a</sup>;

R<sub>9</sub> represents C<sub>1</sub>-10 alkyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>1</sub>-6 alkoxy, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-8 cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-10 heterocyclyl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>6</sub>-10 aryl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>5</sub>-10 heteroaryl, or -N(R)<sub>2</sub> wherein said alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionally substituted with 1-3 groups selected from R<sup>a</sup>;

R<sup>a</sup> represents F, I, CF<sub>3</sub>, N(R)<sub>2</sub>, NO<sub>2</sub>, -COR<sub>8</sub>, -CONHR<sub>8</sub>, -CON(R<sub>8</sub>)<sub>2</sub>, -O(CH<sub>2</sub>)<sub>n</sub>COOR, -NH(CH<sub>2</sub>)<sub>n</sub>OR, -OCF<sub>3</sub>, -NHCOR, -SO<sub>2</sub>R, -SO<sub>2</sub>NR<sub>2</sub>, -SR, (C<sub>1</sub>-C<sub>6</sub> alkyl)O-, -(CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>m</sub>OR, -(CH<sub>2</sub>)<sub>n</sub>C<sub>1</sub>-6 alkoxy, (aryl)O-, (C<sub>1</sub>-C<sub>6</sub> alkyl)S(O)<sub>m</sub>-, H<sub>2</sub>N-C(=NH)-, (C<sub>1</sub>-C<sub>6</sub> alkyl)C(O)-, (C<sub>1</sub>-C<sub>6</sub> alkyl)OC(O)NH-, -(C<sub>1</sub>-C<sub>6</sub> alkyl)NR<sub>w</sub>(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-10 heterocyclyl-R<sub>w</sub>, -(C<sub>1</sub>-C<sub>6</sub> alkyl)O(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-10 heterocyclyl-R<sub>w</sub>, -(C<sub>1</sub>-C<sub>6</sub> alkyl)S(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-10 heterocyclyl-R<sub>w</sub>, -(C<sub>1</sub>-C<sub>6</sub> alkyl)-C<sub>3</sub>-10 heterocyclyl-R<sub>w</sub>, -(CH<sub>2</sub>)<sub>n</sub>Z<sup>1</sup>-C(=Z<sup>2</sup>)N(R)<sub>2</sub>, -(C<sub>2</sub>-6 alkenyl)NR<sub>w</sub>(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-10 heterocyclyl-R<sub>w</sub>, -(C<sub>2</sub>-6 alkenyl)O(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-10 heterocyclyl-R<sub>w</sub>, -(C<sub>2</sub>-6 alkenyl)S(CH<sub>2</sub>)<sub>n</sub>C<sub>3</sub>-10 heterocyclyl-R<sub>w</sub>, -(C<sub>2</sub>-6 alkenyl)-Z<sup>1</sup>-C(=Z<sup>2</sup>)N(R)<sub>2</sub>, -(CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>R, -(CH<sub>2</sub>)<sub>n</sub>SO<sub>3</sub>H, -(CH<sub>2</sub>)<sub>n</sub>PO(OR)<sub>2</sub>, -(CH<sub>2</sub>)<sub>n</sub>OPO(OR)<sub>2</sub>, -O(CH<sub>2</sub>)<sub>n</sub>SO<sub>2</sub>R, -O(CH<sub>2</sub>)<sub>n</sub>PO(OR)<sub>2</sub>, -O(CH<sub>2</sub>)<sub>n</sub>OPO(OR)<sub>2</sub>, cyclohexyl, morpholinyl, piperidyl, pyrrolidinyl, thiophenyl, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thieryl, furyl, isothiazolyl, C<sub>2</sub>-6 alkenyl, and C<sub>1</sub>-C<sub>10</sub> alkyl, said alkyl, alkenyl, alkoxy, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thieryl, furyl, and isothiazolyl optionally substituted with 1-3 groups selected from C<sub>1</sub>-C<sub>6</sub> alkyl, COOR, SO<sub>3</sub>H, OH, F, Cl, Br, I, and -O(CH<sub>2</sub>)<sub>n</sub>CH(OH)CH<sub>2</sub>SO<sub>3</sub>H;

Z<sup>1</sup> and Z<sup>2</sup> independently represents NR<sub>w</sub>, O, CH<sub>2</sub>, or S;

m is 0-3;

n is 0-3;

q is 0-2;

r is 1-6 and

p is 0-2.

U.S.S.N. 10/561,571  
CASE NO. 21406YP  
PAGE NO. 5

17(New). A compound according to claim 16 wherein Y is -CO(CH<sub>2</sub>)<sub>n</sub>, -(CH<sub>2</sub>)<sub>r</sub> or CH(OR) and Q is N or CRy.

18(New). A compound according to claim 17 wherein R<sub>6</sub> is C<sub>1-10</sub> alkyl, (CH<sub>2</sub>)<sub>n</sub>C<sub>6-10</sub> aryl, (CH<sub>2</sub>)<sub>n</sub>C<sub>5-10</sub> heteroaryl, (CH<sub>2</sub>)<sub>n</sub>C<sub>3-10</sub> heterocyclyl, or (CH<sub>2</sub>)<sub>n</sub>C<sub>3-8</sub> cycloalkyl, said aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of Ra, Y is -CO(CH<sub>2</sub>)<sub>n</sub>, Q is N, and R<sub>2</sub> and R<sub>3</sub> are independently selected from C<sub>1-10</sub> alkyl, (CH<sub>2</sub>)<sub>n</sub>C<sub>3-8</sub> cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>-5~10-membered heteroaryl, -(CH<sub>2</sub>)<sub>n</sub>C<sub>6-10</sub> aryl, -(CH<sub>2</sub>)<sub>n</sub>-3~10-membered heterocyclyl, and C<sub>1-6</sub> alkylOH said cycloalkyl, aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of Ra.

19(New). A compound which is:  
1-(1-Benzyl-6-methoxy-1H-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,  
1-(1-benzyl-5-methoxy-1H-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,  
1-(5-Methoxy-1H-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,  
Methyl [2-(2,2-dimethylpropanoyl)-6-methoxy-1H-benzimidazol-1-yl]acetate,  
Methyl [2-(2,2-dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]acetate,  
[2-(2,2-Dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]acetic acid,  
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]-N,N-bis(3-methylbutyl)acetamide,  
1-(Diethoxymethyl)-6-methoxy-1H-benzimidazole,  
1-(diethoxymethyl)-5-methoxy-1H-benzimidazole,  
1-(6-Methoxy-1H-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,  
N,N-Dibutyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]acetamide,  
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]-N,N-diisobutylacetamide,  
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]-N,N-dipropylacetamide,  
N-(Cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]-N-propylacetamide,  
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]-N-ethyl-N-(3-methylbutyl)acetamide,  
N-Butyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]-N-ethylacetamide,  
N-Cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]-N-ethylacetamide,  
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]-N-ethyl-N-1,3-thiazol-2-ylacetamide,

U.S.S.N. 10/561,571  
CASE NO. 21406YP  
PAGE NO. 6

[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetic acid,  
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-bis(3-methylbutyl)acetamide,  
*N,N*-Dibutyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetamide,  
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-diisobutylacetamide,  
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-dipropylacetamide,  
*N*-(Cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,  
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-(3-methylbutyl)acetamide,  
*N*-Butyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,  
*N*-Cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,  
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-1,3-thiazol-2-ylacetamide,  
*N*-(3,3-Dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,  
1-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,  
1-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,  
1-(1-Benzyl-5-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,  
1-(1-Benzyl-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,  
1-[1-(3,3-Dimethylbutyl)-5-methoxy-1*H*-benzimidazol-2-yl]-2,2-dimethylpropan-1-one,  
1-[1-(3,3-Dimethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl]-2,2-dimethylpropan-1-one,  
*N,N*-Dibutyl-2-[2-(2,2-dimethylpropyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetamide,  
*N,N*-Dibutyl-2-[2-(2,2-dimethylpropyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetamide,  
1-[2-(2,2-Dimethylpropyl)-5-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,  
1-[2-(2,2-Dimethylpropyl)-6-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,  
1-[5-Methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,  
1-[6-Methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,  
1-(5-Methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,  
1-(6-Methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,  
1-(2-Benzyl-5-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,  
1-(2-Benzyl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,  
1-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,  
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-dibutylacetamide,

U.S.S.N. 10/561,571  
CASE NO. 21406YP  
PAGE NO. 7

2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,  
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-butyl-*N*-ethylacetamide,  
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-dipropylacetamide,  
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(*tert*-butyl)-*N*-ethylacetamide,  
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-ethyl-*N*-1,3-thiazol-2-ylacetamide,  
[6-methoxy-1-(3-methylbutyl)-1*H*-benzimidazol-2-yl](phenyl)methanone,  
[1-(2-ethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl](phenyl)methanone,  
[1-(3,3-dimethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl](phenyl)methanone,  
*N*-benzyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,  
2-(2-isobutryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,  
*N,N*-dibutyl-2-(2-isobutryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,  
*N,N*-diisobutyl-2-(2-isobutryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,  
2-(2-isobutryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-dipropylacetamide,  
*N*-(cyclopropylmethyl)-2-(2-isobutryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,  
*N*-ethyl-2-(2-isobutryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(3-methylbutyl)acetamide,  
*N*-butyl-*N*-ethyl-2-(2-isobutryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,  
*N*-cyclohexyl-*N*-ethyl-2-(2-isobutryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,  
*N*-butyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,  
1-(1-{2-[trans-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,  
1-(1-{2-[cis-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,  
1-(2-isobutryl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,  
*N*-(3,3-dimethylbutyl)-*N*-ethyl-2-(2-isobutryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,  
*N*-butyl-2-(2-isobutryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,  
*N*-(3,3-dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,  
2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-(2,2-dimethylpropyl)-*N*-ethylacetamide,  
2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-bis(3-methylbutyl)acetamide,  
2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-diisobutylacetamide,

U.S.S.N. 10/561,571  
CASE NO. 21406YP  
PAGE NO. 8

*N*-(3,3-dimethylbutyl)-*N*-ethyl-2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,  
2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-bis(3-methylbutyl)acetamide,  
*N*-(3,3-dimethylbutyl)-2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N*-propylacetamide,  
*N*-(3,3-dimethylbutyl)-*N*-ethyl-2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,  
*N,N*-bis(3,3-dimethylbutyl)-2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,  
2-{2-[(4-cis-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-bis(3-methylbutyl)acetamide,  
2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,  
*N,N*-dibutyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,  
2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-diisobutylacetamide,  
*N*-(3,3-dimethylbutyl)-*N*-ethyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,  
*N*-butyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,  
*N*-(3,3-dimethylbutyl)-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,  
*N*-ethyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(3-methylbutyl)acetamide,  
1-{1-[2-(1-adamantyl)-2-oxoethyl]-6-methoxy-1*H*-benzimidazol-2-yl}-2,2-dimethylpropan-1-one,  
1-{1-[2-(1-adamantyl)-2-oxoethyl]-6-methoxy-1*H*-benzimidazol-2-yl}-2-methylpropan-1-one,  
1-(2-benzyl-5-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,  
1-(5-methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,  
1-[5-methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,  
or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

U.S.S.N. 10/561,571  
CASE NO. 21406YP  
PAGE NO. 9

20(New). A method for treating ocular hypertension or glaucoma comprising administration to a patient in need of such treatment a therapeutically effective amount of a compound of structural formula I of claim 16.

21(New). A method for treating macular edema or macular degeneration, comprising administration to a patient in need of such treatment a pharmaceutically effective amount of a compound of claim 16; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

22(New). A composition comprising a compound of formula I of claim 16 and a pharmaceutically acceptable carrier.

23(New). The composition according to Claim 22 wherein the compound of formula I is applied as a topical formulation, said topical formulation administered as a solution or suspension and optionally containing xanthan gum or gellan gum.

24(New). A composition according to claim 23 optionally containing one or more of a  $\beta$ -adrenergic blocking agent selected from the group consisting of timolol, betaxolol, levobetaxolol, carteolol, and levobunolol; a parasympathomimetic agent selected from the group consisting of pilocarpine; a sympathomimetic agent selected from the group consisting of epinephrine, brimonidine, iopidine, clonidine, and para-aminoclonidine, a carbonic anhydrase inhibitor selected from the group consisting of dorzolamide, acetazolamide, metazolamide and brinzolamide; a prostaglandin selected from the group consisting of latanoprost, travaprost, unoprostone, rescula, and S1033, a hypotensive lipid selected from the group consisting of lumigan, a neuroprotectant selected from the group consisting of eliprodil, R-eliprodil and memantine; and a 5-HT2 receptor agonist selected from the group consisting of 1-(2-aminopropyl)-3-methyl-1H-imidazol-6-ol fumarate and 2-(3-chloro-6-methoxy-indazol-1-yl)-1-methyl-ethylamine.